Because the de novo DNA methyltransferase DNMT3A is mutated in more than 22% of AML, we wanted to determine if either of the other catalytically active DNMT protein family members, DNMT1 or DNMT3B, can exhibit a synthetic lethal relationship with DNMT3A mutation. This evidence concerns the gene DNMT3A and acute myeloid leukemia.